Trials / Completed
CompletedNCT00280059
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 660 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | dose 150-600 mg/day given BID |
| DRUG | Lamotrigine | dose 100-500 mg/day given BID |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2009-12-01
- Completion
- 2010-04-01
- First posted
- 2006-01-20
- Last updated
- 2021-01-28
- Results posted
- 2011-10-24
Locations
102 sites across 29 countries: Belgium, Bulgaria, China, Colombia, Czechia, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Portugal, Romania, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00280059. Inclusion in this directory is not an endorsement.